Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment

Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related fatalities globally [1,2]. Identification of activating epidermal growth factor receptor (EGFR) mutations has shifted the treatment paradigm for NSCLC [3 –5]. First/second-generation EGFR-tyrosine kinase inhibitors (TKIs) have been developed and have become the standard of care in advanced NSCLC patients harboring sensitive EGFR mutation (exon 19 deletion or L858R) [5–7]. However, drug resistance would eventually happen, and secondary T790M mutat ion located at exon 20 of the EGFR gene accounts for over 50 % of the acquired resistance mechanism [8,9].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research